Physician profile
Abid Majid
NPI 1902828486
$12,497.31
in general payments reported to CMS, 2019-2025
32 companies · $2,428 in 2025
The $2,428 reported for 2025 was more than what 88% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,348 · 2020: $1,514 · 2021: $1,199 · 2022: $1,775 · 2023: $1,959 · 2024: $2,274 · 2025: $2,428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,419 · Education: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,419.03 |
| Education | $242.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,566.25 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,456.51 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Glaxosmithkline, LLC. | $2,146.20 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Mylan Specialty L.P. | $851.24 | 2019-2024 | Yupelri |
| Sunovion Pharmaceuticals INC. | $592.53 | 2019-2020 | |
| Harmony Biosciences LLC | $252.28 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $251.93 | 2021-2025 | Dupixent |
| Viatris Specialty LLC | $234.49 | 2025 | Yupelri |
| Intuitive Surgical, INC. | $205.31 | 2023-2024 | Da Vinci Surgical System |
| United Therapeutics Corporation | $202.23 | 2022-2025 | Tyvaso, Tyvaso, Orenitram |
| Genzyme Corporation | $202.18 | 2020-2025 | |
| Amgen INC. | $194.18 | 2024-2025 | Tezspire |
| Ethicon INC. | $158.57 | 2022 | |
| Advanced Respiratory, INC | $144.18 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $139.13 | 2024-2025 | Winrevair |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $135.04 | 2022-2024 | Veklury |
| Sanofi-Aventis U.S. LLC | $131.98 | 2024-2025 | |
| Baxter Healthcare | $100.47 | 2022-2023 | Hillrom - Vest System Model 105 Home Care |
| Genentech USA, INC. | $95.75 | 2019-2021 | |
| Insmed, INC. | $77.06 | 2025 | Brinsupri, Arikayce |
| Vanda Pharmaceuticals INC. | $73.53 | 2023-2024 | Hetlioz |
| Mallinckrodt Hospital Products INC. | $47.70 | 2022-2025 | Acthar |
| Inspire Medical Systems, INC. | $43.45 | 2024 | Inspire |
| Itamar Medical INC | $29.04 | 2023 | Watchpatone |
| Verona Pharma, INC. | $25.92 | 2025 | Ohtuvayre |
| Pulmonx Corporation | $25.57 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Takeda Pharmaceuticals U.S.A., INC. | $22.79 | 2020 | |
| Grifols USA, LLC | $22.73 | 2019 | |
| Electromed, INC. | $21.19 | 2025 | Smartvest |
| Resmed Corp | $17.39 | 2019 | |
| Irhythm Technologies, INC. | $16.83 | 2021 | |
| Circassia INC. | $13.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abid Majid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.